Clinical Core

临床核心总结 临床核心的总体目标将是为大型 临床人群，特别强调受试者的纵向跟踪，以提供良好的 由红十字与红新月会调查人员和合作者进行的研究项目的特色化主题。重要 耶鲁大学ADRC的临床核心重点广泛地包括细胞生物学，整合 翻译神经科学，并强调当前和未来生物标本的系统储存 生物标志物研究。而生物标记物在阿尔茨海默病(AD)诊断和治疗中的重要性 尽管最近靶向蛋白质组学方面的进展还没有在这一领域得到应用，但人们对这一领域的研究进展还是很满意的。 耶鲁大学ADRC生物标记物/病理学核心和具体研究项目将寻求开发这些方法 与阿尔茨海默病及相关疾病相关。在这些努力的合作下，临床核心将进行 收集了广泛的生物标记物样本，横断面和 在整个AD过程中，纵向上。目标1将用于评估和招收大约 将进入核心人群参与五个诊断类别研究的500名受试者 AD的完整连续体(从临床前到痴呆)，以及非AD痴呆和正常对照组。一个 耶鲁大学ADRC特别感兴趣的诊断类别是认知正常的中年人(50-65岁)一级 患AD的亲属具有不同的APOE4遗传风险。目标2将把这500名受试者纳入统一数据集中 (UDS)人群，并将UDS措施提供给国家阿尔茨海默氏症协调中心 (NACC)用于国家研究。AIM 3将招收受试者参加尸检计划。AIM 4将提供适当的 ADRC附属临床研究的受试者。AIM 5将收集和分发生物标本 给ADRC和其他研究人员进行生物标记物研究。这些AIMS将为ADRC附属调查人员提供 测试生物标记物的现成能力曾在AD痴呆的早期阶段得到验证 发病机制。

SUMMARY FOR CLINICAL CORE The over-arching goal of the Clinical Core will be to provide research diagnostic evaluations for a large clinical population with a special emphasis on subjects who are followed longitudinally to provide well- characterized subjects for the research projects conducted by ADRC investigators and collaborators. Important focuses of the Clinical Core as for the Yale ADRC broadly include cell biology, the integration of translational neuroscience, and an emphasis on systematic storage of biospecimens for current and future biomarker studies. While the importance of biomarkers for Alzheimer's disease (AD) diagnosis and therapeutic development is well appreciated, recent advances in targeted proteomics have not been deployed in this field. The Yale ADRC Biomarker/Pathology Core and specific Research Projects will seek to develop these methods with relevance to AD and related disorders. In partnership with these efforts, the Clinical Core will undertake the collection of a wide range of biomarker specimens across the full spectrum of AD cross-sectionally and during the full course of AD longitudinally. Aim 1 will provide for the evaluation and enrollment of approximately 500 subjects who will enter the Core Population for participation in research in five diagnostic categories on the full continuum of AD (from preclinical to dementia), as well as non-AD dementias and normal controls. A diagnostic category of special interest for the Yale ADRC is cognitively normal middle-aged (50-65) first-degree relatives at varying APOE4 genetic risk for AD. Aim 2 will enroll these 500 subjects in the Uniform Data Set (UDS) population and make the UDS measures available to the National Alzheimer's Coordinating Center (NACC) for national studies. Aim 3 will enroll subjects into the Autopsy Program. Aim 4 will provide appropriate subjects for the clinical studies affiliated with the ADRC. Aim 5 will collect and distribute biological specimens to ADRC and other researchers for biomarker studies. These Aims will provide ADRC affiliated investigators the ready ability to test biomarkers once validated in AD dementia in the earliest stages of AD pathogenesis.